NCT02683798 is a NA clinical trial of Continuous energy restriction in Obesity, sponsored by NHS Greater Glasgow and Clyde.

Who is sponsoring NCT02683798?

NCT02683798 is sponsored by NHS Greater Glasgow and Clyde.

What drugs are being tested in NCT02683798?

Interventions in NCT02683798: Continuous energy restriction, Intermittent energy restriction.

Is NCT02683798 still recruiting?

NCT02683798 is currently completed. Last updated 28 April 2021.

Last reviewed 2021-04-28 · How we verify

NCT02683798

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BEYOND Weight Loss Maintenance Study

Completed NA Last updated 28 April 2021

What this trial tests

NA trial testing Continuous energy restriction in Obesity in 63 participants. Completed in 22 November 2019.

Timeline

12 April 2016

Primary endpoint
22 November 2019

22 November 2019

Quick facts

Lead sponsor	NHS Greater Glasgow and Clyde
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	63
Start date	12 April 2016
Primary completion	22 November 2019
Estimated completion	22 November 2019
Sites	3 locations across United Kingdom

Drugs / interventions tested

Continuous energy restriction
Intermittent energy restriction

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

NHS Greater Glasgow and Clyde — full company profile →

Who can join

Adults 20 to 65, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study to determine the effectiveness of two weight loss maintenance interventions in Counterweight Plus, a structured weight management programme.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Diet strategies for maintaining substantial therapeutic weight loss: 78-week mixed methods randomised trial.
Brosnahan N, Hankey C, Leeds A, Leslie W, et al · · 2025
Diet strategies for maintaining substantial therapeutic weight loss: 78-week mixed methods randomised trial.
Brosnahan N, Hankey C, Leeds A, Leslie W, et al · · 2025 · PMID 40934815 · DOI 10.1016/j.clnu.2025.08.009

Verify or expand the search:

Other trials of Continuous energy restriction

Trials testing the same drug.

NCT04138160 — Effects of Two Weeks of 5:2 Intermittent Energy Restriction on Basal and Postprandial Metabolism · NA · completed

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other NHS Greater Glasgow and Clyde trials

Trials by the same sponsor.

NCT07403890 — Rewiring the Brain-Immune Axis for Chronic Pain Using Transcranial Magnetic Stimulation in Psoriatic Arthritis · NA · not yet recruiting
NCT07372508 — Glasgow Low-dose CT and AI-based Diagnostics to Case Find Lung Cancer and Other Cardio-respiratory Long-term Conditions · NA · not yet recruiting
NCT07391280 — Strategy for EArly Recognition of Cancer, COPD & Heart Failure in the Emergency Department · NA · not yet recruiting
NCT07048184 — Sarcoma Surgery Wound Complications Comparing Usual Versus Negative Pressure Dressing · Phase 2 · not yet recruiting
NCT06786936 — Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02683798 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NHS Greater Glasgow and Clyde
Last refreshed: 28 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02683798.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing